{"id":"W2937367049","doi":"10.1002/cpt.1477","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz‐Containing Antiretroviral Therapy","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"European and Developing Countries Clinical Trials Partnership; National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Human Genome Research Institute; National Institute on Minority Health and Health Disparities; Canadian Institutes of Health Research; National Institutes of Health; Partnership for Advanced Computing in Europe AISBL","keywords":"Efavirenz; CYP2B6; Discontinuation; Medicine; Reverse-transcriptase inhibitor; Pharmacogenetics; Adverse effect; Guideline; Pharmacology; Internal medicine; Oncology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology; Genotype; Cytochrome P450; Biology; CYP1A2; Viral load; Pathology; Genetics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01575394,0.0008798568,0.001410289,0.001943525,0.001190483,0.003012245,0.00406791,0.009828264,0.010812],"category_scores_gemma":[0.0381587,0.0007744779,0.002852358,0.002264873,0.001215501,0.001743069,0.001916251,0.01107094,0.008043305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002562755,"about_ca_system_score_gemma":0.02148149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01958122,"about_ca_topic_score_gemma":0.02795385,"domain_scores_codex":[0.9788166,0.008844106,0.00442558,0.0006704585,0.006128555,0.001114689],"domain_scores_gemma":[0.9634508,0.0106181,0.003707359,0.001198739,0.0186877,0.002337315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001415062,0.0003265057,0.001210444,0.001278541,0.00005873159,0.000652027,0.0002428958,0.0007303673,0.0009121402,0.01140336,0.8307925,0.1522509],"study_design_scores_gemma":[0.0002915837,0.000161752,0.004227577,0.005665788,0.0001219852,0.001014743,0.0001535812,0.0007274018,0.0008131312,0.006443522,0.9803191,0.00005996056],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.0050017,0.05552799,0.07486542,0.4616271,0.0162491,0.008894,0.01433379,0.003410183,0.3600908],"genre_scores_gemma":[0.0461449,0.07730211,0.2808393,0.4051983,0.009476727,0.01866048,0.03258912,0.001416221,0.1283729],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.01958122,"threshold_uncertainty_score":0.08331579,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1044532864015122,"score_gpt":0.4935270597406963,"score_spread":0.389073773339184,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}